Abstract in Medical Technology

Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology

MELBOURNE, Australia, May 15 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) today announced that the abstract for its upcoming oral presentation on CYT997 at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) will be accessible to the public via ASCO's website (...

American Society of Clinical Oncology (ASCO) Accepts New Data on AVR118 for Publication in 2007 Abstract Book

YONKERS, N.Y.--(BUSINESS WIRE)--Mar 7, 2007 - Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that new information on AVR118 has been accepted for publication in the 2007 Proceedings of the American Society of Clinical Oncology (ASCO) Abstract ...

Pro-Pharmaceuticals to Present Abstract at the International Society of Oncodevelopmental Biology and Medicine Conference

NEWTON, Mass.--(BUSINESS WIRE)--May 17, 2007 - Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel, first-in-class carbohydrate compounds today announced that Eliezer Zomer, Ph.D., Executive Vice President, Product Development and Manufacturing will present, "Pharmacokinetic Translational S...

Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions

EXETER, N.H.--(BUSINESS WIRE)--May 24, 2007 - Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced that a late breaking abstract sponsored by the Company has been accepted for a poster presentation at the American Diabetes Association 67th Scientific Sessio...

VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC, a privately held biotechnology and healthcare product development company, announced today that its late-breaking abstract has been accepted as a poster presentation at the 67th Scientific Sessions of the American Diabetes Association...

VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, announced that Abstract #2209-PO, Evaluation of Glycemic Parameters in Obese Diabetic Patients Treated with P...

Neurointerventionists Expand Research to Quality of Life in Aneurysm Patients Following Minimally Invasive Coiling Treatment

...n severe disability, or even death), less is known about the psychosocial functioning of these patients after undergoing the coiling treatment. In an abstract presented yesterday at the Society of NeuroInterventional Surgery (SNIS) 6th Annual Meeting in Boca Raton, FL, Antonio DeSimone, M.D., a neuroradiolog...

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

... of partial epilepsy with eslicarbazepine acetate. abstract presented at the 28th International Epilepsy Congr...amazepine in patients with partial-onset seizures. abstract presented at the 28th International Epilepsy Congr...treatment in patients with partial-onset seizures. abstract presented at the 28th International Epilepsy Congr...

Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)

...fforts to help the clinical development community to reduce time-to-market, cut costs, and improve portfolio returns." The CRADA Research Plan abstract The Center for Devices and Radiological Health (CDRH) at the FDA encourages sponsors to use innovative Bayesian designs for clinical trials involvi...

Clinical and Histopathological Results Using Pollogen's TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy

... Dr. Andrea Gat, has been published in the June issue of the Journal of Cosmetic and Laser Therapy (Volume 11, Issue 2 June 2009 , pages 78 - 84). The abstract is available online at: http://www.informaworld.com/smpp/content~db=all~content=a910865593?words=kapl an&hash=843258562 (Due to the lengt...

Neurocrine Biosciences Presents Elagolix Data

...ciety (ENDO 09) in Washington DC, June 10-13, 2009. The first clinical abstract presentation at ENDO 09 reviews the results of a Phase I study in which ela... comparable among the placebo and elagolix groups. The second clinical abstract at ENDO 09 reports results from a Phase II study where the safety of elagol...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

...) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing Phase II study. 14th Congress of the EHA 2009, abstract no. 482 Webcast/Conference Call Micromet will host a webcast/conference call this morning from 9:00 am to 11:00 am U.S. Eastern time ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

...i-CD19/-CD3 bispecific BiTE(R) antibody blinatumomab. 14th Congress of EHA, abstract number 430 (2) Bargou, R. et al. (2008). Sustained Response Duratio...e Ongoing Phase I Study MT103-104 in Patients with Relapsed NHL. ASH 2008, abstract number 267 Webcast/Conference Call Micromet will host a webcast...

Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting

...delivery system is CE Mark approved and has been used in over 50 procedures at cardiac centers outside the U.S. It is not currently FDA approved. The abstract " One Year Follow up of Combined Autologous Bone Marrow Derived Progenitor Cell Therapy and Transmyocardial Laser Revascularization for Diffuse Nongra...

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

...g the disease - through the entire spectrum of care from prevention, diagnosis, and treatment to survivorship and end of life care. For information on abstract embargo schedules and other ASCO information and resources, visit http://www.asco.org/presscenter . About BSI-201 Among other investiga...

Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer

...iglumex (50mg/m2) and cisplatin 25mg/m2 for six weeks with concurrent 50.5Gy of radiation. Twenty-three eligible patients were enrolled at the time of abstract submission. Five of the first 11 patients (45%) who underwent resection had a pathologic complete response. A prophylactic feeding tube was not routin...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

... at the American Society of Clinical Oncology's (ASCO) 2009 Annual Meeting in Orlando, Fla. (abstract #5011). Additionally, ASCO selected the MDV3100 abstract for inclusion in its Best of ASCO(R) program, an educational initiative covering highlights from the ASCO Annual Meeting to increase global access to ...

Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative

... abstract # 6053 ORLANDO, Fla., June 1 /PRNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data demonstrating th...

Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions

... - Late-Breaking abstract Accepted - SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall/ -- Arena Pha...rmaceuticals, Inc. (Nasdaq: ARNA ) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

...in combination with capecitabine as a treatment for advanced colon cancer. abstract #4081, entitled, "Randomized phase II study of perifosine in combination wi... investigators for their dedication to this clinical trial." A copy of abstract #4081 is currently available and can be viewed on-line through the ASCO web...

Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)

...-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)) product candidate. (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ) abstract 3017: A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)), in Relapsed and Refractory CLL -- Early Promising Clinic...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

...once systemic metastases become evident[ii]. About the study ASCO abstract #9000: Monday 1 June 2009, 16:30-18:00, EDT Level 4, Valencia Room, W415A ...used or mentioned in this release are protected by law. [i] ASCO 2009, abstract #9000: "Phase 1 study of PLX4032: Proof-of-concept for V600E BRAF mutation ...

Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

...The data presented today in an oral presentation ( abstract 157: Effect of Linaclotide on IBS-C Symptoms...ng made this week at DDW will be: abstract 236: Global Endpoints in IBS Clinical Trials: Resu... 2:30 p.m. CT; McCormick Place, Room E352 abstract 418: Effect of Linaclotide on Quality of Life in A...

Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients

....m. EDT, and as an oral presentation at the meeting at 10:30 a.m. EDT (ASCO abstract #CRA5507).(2) With 515 patients evaluated, the data showed a statistic...ncurrent Cisplatin And Radiation In Cancer Of The Cervix Stages IIb To Iva. abstract #CRA5507, 45th American Society of Clinical Oncology (ASCO) annual meeting ...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

...in combination with capecitabine as a treatment for advanced colon cancer. abstract #4081, entitled, "Randomized phase II study of perifosine in combination wi... investigators for their dedication to this clinical trial." A copy of abstract #4081 is currently available and can be viewed on-line through the ASCO web...

Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy

... abstract # 25670 ORLANDO, Fla., May 29 /PRNewswire-USNewswire/ -- The American Society of Clinical Oncology (ASCO) has selected new breast cancer research...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

...kt-inhibitor for cancer, as a treatment for advanced renal cell carcinoma. abstract #5034, entitled, "Phase II study of perifosine in metastatic renal cell car...ial designs in patients with advanced renal cell carcinoma." A copy of abstract #5034 is currently available and can be viewed on-line through the ASCO web...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

... Duh, Analysis Group, Inc., Boston, MA abstract e20596, Publication only ...ry's Medical Center, San Francisco, CA abstract e20004, Publication only ...ity of Pennsylvania , Philadelphia, PA abstract 2, Plenary Presentation, Sunday, May 31, 1:00 PM t...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... Early stage development data abstract #8542: Panobinostat + lenalidomide and dexamethas... abstract #3563: TKI258 (dovitinib lactate) in metastatic r... abstract #3533: Pharmacodynamics and pharmacokinetics of A...

Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop

...ncorporated in October 2008, were presented: abstract book page 27: Prophylactic Therapy Considerations in Hereditary Angioedema In an abstract entitled, 'When Should Prophylactic Therapy be Co... for prophylaxis of HAE in the U.S.; The abstract suggested that patients with frequent HAE attacks,...

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

...ation details are as follows: TRC105 abstract Title: Phase 1 study of TRC105 (anti-CD105 (endogl...erapeutics Session Type: Poster Discussion abstract Number: 3518 TRC102 abstract Title: A Phase 1 study of daily oral TRC102 (metho...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

...n with castrate resistant prostate cancer (CRPC). abstract #5062; Poster Board #17; Poster Discussion, May 31...in men with docetaxel refractory prostate cancer. abstract #5145; Poster Board #J13; GU General Poster Sessio...T-101 in recurrent glioblastoma multiforme (GBM). abstract #2010; Poster Board #2; Poster Discussion, May 30,...

Telik Announces Presentation at ASCO Annual Meeting

...Clinical Oncology (ASCO) which will be held from May 29 to June 2 in Orlando, FL. Details of the presentation are as follows: -- abstract #5552 - General Poster Session, Gynecologic Cancer; Sunday, May 31, 2009, 2:00-6:00pm EDT; Level 2, West Hall C Title: "...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

... - June 2, 2009 in Orlando, FL. The results are to be presented in an abstract (number 6018) entitled, "Phase I/II dose escalation study of OncoVEX GM-CSF...urred locally in the neck at a median follow up of 26 months at the time of abstract submission. Three patients had distant metastatic disease. Two of these wer...

Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting

...ion that will be held from 2:00 PM-6:00 PM Eastern Time. The presentation, abstract #8523, is titled, "Randomized Phase III trial of pixantrone compared with o... single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma." The abstract is available at www.asco.org . CTI expects to complete the submiss...

Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy

...nstrating that its lead candidate, ARC-4558, significantly reduced pain caused by diabetic neuropathy in a double-blind, placebo-controlled trial. The abstract will be presented in a poster session on May 8th from 4:00-5:30 PM at the American Pain Society Annual Meeting, held May 7-9 in San Diego. ARC-4558 is...

Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology

...irst-line treatment of castration-resistant prostate cancer abstract #5140 R. De Jager, L. Roman, N. Lopatkin, P. Karlov, H. Breitz, R. ...dified FOLFOX-6 as first-line therapy for colorectal cancer abstract #4026 R. Earhart, S. Cheporov, O. Gladkov, M. Biakhov, H. Breitz, R...

Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia

...tic hyperplasia (BPH). D-3263 demonstrated the ability to reduce BPH alone and in combination with finasteride, a current treatment for BPH. The abstract (#1408), "Preclinical Evaluation of the TRPM8 Ion Channel Agonist D-3263 for Benign Prostatic Hyperplasia" is being presented at the American Urologic...

Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms

... neither as safe nor effective as branded medications: experience in men treated for lower urinary tract symptoms (LUTS). J Urol, suppl. 2009: 181, 4, abstract 1799 About the American Urological Association: Founded in 1902 and headquartered near Baltimore , Maryland , the American Urological ...

New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health

...y authors during the panel press conference: abstract 576: Is statin use associated with prostate cancer...nd lower risk of positive surgical margins. abstract 1598: Statin medication use and the risk of bioche...hemical recurrence following prostatectomy. abstract 574: Associations between statin use and prostate-...